A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation

Study Summary

The reason for this study is to see if the study drug selpercatinib is safe and effective in participants in China with rearranged during transfection (RET) fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.

Conditions

Solid Tumor Medullary Thyroid Cancer

Interventions / Drugs

Selpercatinib

View on ClinicalTrials.gov ↗

Sponsor

LLY

Eli Lilly and Company

Diabetes/Oncology

C53/100

Study Details

Enrollment77 participants

Primary Completion—

Lead SponsorEli Lilly and Company

Data Retrieved2026-04-11 02:55:33.865752+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.